Adaptive Biotechnologies (ADPT) Net Cash Flow (2018 - 2026)

Adaptive Biotechnologies has disclosed Net Cash Flow across 9 years of filings, most recently posting $92.3 million for Q2 2026.

• In Q2 2026, Net Cash Flow rose 1335.09% year-over-year to $92.3 million; the TTM figure through Jun 2026 stood at $126.7 million (up 849.06% YoY), while the FY2025 annual figure was $22.4 million, up 230.2% from the prior year.
• Net Cash Flow came in at $92.3 million for Q2 2026 at Adaptive Biotechnologies, up from $7.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $141.1 million in Q3 2022 to a low of -$127.6 million in Q4 2022.
• Average Net Cash Flow over 5 years is $1.7 million, with a median of $3.5 million recorded in 2023.
• Year-over-year, Net Cash Flow tumbled 865.46% in 2022 and surged 1335.09% in 2026.
• Over 5 years, Net Cash Flow stood at -$127.6 million in 2022, then soared by 81.47% to -$23.6 million in 2023, then surged by 141.27% to $9.8 million in 2024, then jumped by 58.49% to $15.5 million in 2025, then jumped by 497.06% to $92.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $92.3 million in Q2 2026, $7.1 million in Q1 2026, and $15.5 million in Q4 2025.